



**THE FOUNDATION  
FOR SECURE  
MARKETS®**

#54171

**Date:** February 22, 2024

**Subject:** Gracell Biotechnologies Inc. - Cash Settlement  
Option Symbol: GRCL  
Date: 02/22/2024

On February 20, 2024, Shareholders of Gracell Biotechnologies Inc. (GRCL) voted concerning the proposed merger with Grey Wolf Merger Sub, a wholly owned subsidiary of AstraZeneca Treasury Limited. The merger was approved and subsequently consummated before the open on February 22, 2024. As a result, each existing GRCL American Depositary Share will be converted into the right to receive \$10.00 cash, less fees and withholdings, if any, plus five non-transferable Contingent Value Rights ("CVR").

Note: The CVRs represent a non-transferable contractual right to receive a contingent payment. The adjusted GRCL option deliverable will not include the non-transferable CVRs.

#### **Contract Adjustment**

**Date:** February 22, 2024

**New Deliverable  
Per Contract:** \$1,000.00 Cash (\$10.00 x 100), less fees and withholdings, if any

**Settlement:** OCC will delay settlement of the GRCL deliverable until the final net cash merger consideration is confirmed. Once the final amount is determined, settlement in GRCL options will take place through OCC's cash settlement system. Settlement will be accomplished by payment of the difference between the extended strike amount and the cash deliverable.

#### **Acceleration of Expirations**

Pursuant to OCC Rule 807, equity stock option contracts whose deliverables are adjusted to call for cash-only delivery will be subject to an **acceleration of the expiration dates for outstanding option series** (See OCC Information Memo 23988).

#### **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all

information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

**ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.**

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).